Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
Launched by UNIVERSITY OF THE PUNJAB · Nov 3, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for chronic diabetic foot ulcers, which are painful wounds that can occur in people with diabetes. Researchers are looking at two types of stem cells taken from fat tissue, combined with a special substance called platelet-rich plasma (PRP) that helps healing. The goal is to see how well these treatments can help heal these stubborn wounds and to determine which method works best, ensuring that the treatments are safe for patients.
To be eligible for this trial, participants must be between 20 and 60 years old, have Type 1 or Type 2 diabetes, and have a chronic foot ulcer that has lasted between 6 and 24 weeks. They should also have a manageable weight and be able to undergo a liposuction procedure to collect the fat needed for the treatment. Participants can expect to receive close monitoring throughout the trial and will need to provide consent to join. This study is currently recruiting, and it offers a potential new option for those struggling with diabetic foot ulcers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 1 or Type 2 Diabetes Mellitus
- • Age 20-60 years (Male/Female)
- • Body mass index 20-30 kg/m2
- • Suitable for liposuction
- • Condition or Disease: Diabetic Neuropathy
- • Wound Type: Chronic foot ulcer
- • Approx. wound area: 2 cm2 - 8 cm2
- • Wound Condition should be of Wagner's grade I (Limited to soft tissue)
- • Duration of wound persistence: 6-24 Weeks
- • Transcutaneous oxygen pressure \> 30 mmHg, and an ankle brachial pressure index \> 0.5.
- • Already following an adequate off-loading method
- • Provided signed informed consent
- Exclusion Criteria:
- • Uncontrolled hyperglycemia (HbAlc \> 9%)
- • Presence of severe clinical sign of infection
- • Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors.
- • Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases
- • Patients with critical limb ischemia and osteomylitis
- • Withdrawal of informed consent
About University Of The Punjab
The University of the Punjab, a leading institution in higher education and research in Pakistan, is committed to advancing medical knowledge and public health through rigorous clinical trials. With a strong emphasis on ethical standards and scientific integrity, the university aims to contribute to the development of innovative therapeutic solutions and improve patient outcomes. Leveraging its extensive academic resources, interdisciplinary collaboration, and a diverse pool of talented researchers, the University of the Punjab fosters an environment conducive to pioneering research that addresses pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahore, Punjab, Pakistan
Patients applied
Trial Officials
Azra Mehmood, PhD
Principal Investigator
Center of Excellence in Molecular Biology (CEMB, University of the Punjab, Lahore
Sheikh Riazuddin, PhD
Study Director
Jinnah Burn and Reconstructive Surgery Center (JB&RSC), Lahore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials